NewLimit, the anti-aging startup co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in one of biotech's largest funding rounds of 2026.
BioPharma Dive, a biotech industry news outlet, described NewLimit's $435 million Series C as "one of the largest so far this year for a biotechnology firm."
NewLimit said in a June 2 blog post that the round was led by Founders Fund, the venture firm co-founded by Peter Thiel, with new investors including Thrive Capital, Greenoaks and Quiet Capital. "
"Our trial next year will reveal how liver age reprogramming translates into humans for the first time. Over the coming years, we will add new therapeutic programs and bring a diverse portfolio of therapies into the clinic."
NewLimit
NewLimit
- Returning backers also include Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures and Human Capital.
NewLimit, an anti-aging biotech startup co-founded by Coinbase CEO Brian Armstrong, is now valued at about $3.1 billion, according to STAT, a health and medicine publication that cited NewLimit co-founder and CEO Jacob Kimmel.
- NewLimit, founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and computational biologist Jacob Kimmel, is trying to build medicines that restore youthful function in old cells through epigenetic reprogramming.
- The startup plans to bring its first aging reprogramming medicine into human clinical trials next year after finding a prototype medicine that "reverses cell age in old human liver cells."